Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Nov 26

PMID 36428709

Authors

Leonardo Di Gennaro

Raimondo De Cristofaro

Antonietta Ferretti

Maria Basso

Claudia Riccio

Massimo Cordaro

Carlo Lajolo

Affiliations

Soon will be listed here.

Abstract

Venous thromboembolism (VTE) disease is the second leading cause of mortality in cancer patients. In the general population, the annual incidence of a thromboembolic event is about 117 cases per 100,000 persons, but cancer increases this risk about fourfold, while in patients receiving chemotherapy and surgical treatment, it is about sevenfold. Oral squamous cell carcinoma (OSCC) is the most common form of oral cancer and represents a multistep process in which environmental factors and genetic alterations are implicated. Thrombotic risk is considered empirically low in OSCC patients, although few data are available. Having limited information available may result in poor awareness of VTE prevention in OSCC, risking jeopardising the oncologic treatment and increasing the morbidity and mortality among these patients. In this paper, the topic of OSCC-associated thrombosis will be discussed.

Citing Articles

How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism.

Janickova M, Bolek T, Stanciakova L, Nagy N, Mokan M, Samos M Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513923 PMC: 10385582. DOI: 10.3390/ph16071011.

References

Debbie Jiang M, Alfred Ian Lee M . Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treat Res. 2019; 179:87-101. DOI: 10.1007/978-3-030-20315-3_6. View

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

Ikeda A, Yamachika E, Mizutani M, Matsubara M, Moritani N, Nakatsuji K . Rapid occurrence of left ventricular thrombus associated with platinum-based chemotherapy plus cetuximab for the treatment of metastatic squamous cell carcinoma of the head and neck: A case report. Mol Clin Oncol. 2017; 7(5):833-836. PMC: 5700264. DOI: 10.3892/mco.2017.1393. View

Oppelt P, Betbadal A, Nayak L . Approach to chemotherapy-associated thrombosis. Vasc Med. 2015; 20(2):153-61. PMC: 4655120. DOI: 10.1177/1358863X14568705. View

Burgy M, Barthelemy P, Lefevre F, Dupret-Bories A, Truntzer P, Korenbaum C . Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey. Oncology. 2017; 93(1):11-17. DOI: 10.1159/000454732. View

Johnstone S, Logan R . Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2006; 36(3):263-6. DOI: 10.1016/j.ijom.2006.09.017. View

Eisma R, Spiro J, Kreutzer D . Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg. 1997; 174(5):513-7. DOI: 10.1016/s0002-9610(97)00166-9. View

Agnelli G, Becattini C, Bauersachs R, Brenner B, Campanini M, Cohen A . Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thromb Haemost. 2018; 118(9):1668-1678. DOI: 10.1055/s-0038-1668523. View

Khorana A, Francis C, Culakova E, Lyman G . Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104(12):2822-9. DOI: 10.1002/cncr.21496. View

10.

Li H, Zhang Y, Xu M, Yang D . Current trends of targeted therapy for oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2022; 148(9):2169-2186. DOI: 10.1007/s00432-022-04028-8. View

11.

Ando Y, Hayashi T, Sugimoto R, Nishibe S, Ito K, Kawada K . Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs. 2019; 38(4):1200-1206. PMC: 7340643. DOI: 10.1007/s10637-019-00881-6. View

12.

Slotman G . Plasma thromboxane A2 and prostacyclin concentrations in squamous cell carcinoma of the head and neck. J Surg Oncol. 1988; 38(1):33-7. DOI: 10.1002/jso.2930380110. View

13.

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

14.

Mody M, Rocco J, Yom S, Haddad R, Saba N . Head and neck cancer. Lancet. 2021; 398(10318):2289-2299. DOI: 10.1016/S0140-6736(21)01550-6. View

15.

Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi B . Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer. 2017; 17(1):572. PMC: 5574145. DOI: 10.1186/s12885-017-3563-3. View

16.

Farge D, Frere C, Connors J, Ay C, Khorana A, Munoz A . 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 20(10):e566-e581. DOI: 10.1016/S1470-2045(19)30336-5. View

17.

Lee H, Yu N, Lee S, Tsai H, Wu C, Cheng J . Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer. Biomed J. 2020; 43(2):146-162. PMC: 7283562. DOI: 10.1016/j.bj.2019.07.001. View

18.

Grant P, Greene M, Chopra V, Bernstein S, Hofer T, Flanders S . Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med. 2015; 129(5):528-535. PMC: 5331485. DOI: 10.1016/j.amjmed.2015.10.027. View

19.

Kakei Y, Akashi M, Hasegawa T, Minamikawa T, Usami S, Komori T . Incidence of Venous Thromboembolism After Oral Oncologic Surgery With Simultaneous Reconstruction. J Oral Maxillofac Surg. 2015; 74(1):212-7. DOI: 10.1016/j.joms.2015.08.006. View

20.

Lipets E, Ataullakhanov F . Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J. 2015; 13(1):4. PMC: 4310199. DOI: 10.1186/s12959-015-0038-0. View